Vol. 21/No. 5 | OncologyLive

Protect Your Oncology Practice Against Cyber Thieves

March 05, 2020

While cybersecurity upgrades may require additional software and hardware and come at an expense, experts said the expenses are worth it, as they help avoid government fines for data breaches, data recovery costs, and the potential for loss of public trust.

Duvelisib Tested in Rare Lymphoma Subtype

March 04, 2020

Investigators propose that a PI3K-δ,γ inhibitor currently indicated for the treatment of 3 hematologic malignancies may be a key to boosting response rates in peripheral T-cell lymphoma, a disease setting defined by poor prognoses.

Rapid Advances Change the Paradigm in Bladder Cancer

March 04, 2020

Arjun V. Balar, MD, discusses how immunotherapy options are helping to reduce reliance on platinum chemotherapy and cystectomy, as well as further efforts to engage the immune system in the fight against bladder cancer and other pathways toward greater treatment efficacy and quality of life for patients.

Dana-Farber Tackles Rising Incidence of Young-Onset Colorectal Cancer

March 03, 2020

Dana-Farber Cancer Institute launched the Young-Onset Colorectal Cancer Center, among the first of its kind, in March 2019 to provide expert and compassionate clinical care, promote scientific discovery and innovation to elucidate underlying biological mechanisms, identify risk factors, and facilitate development of novel therapies, and improve prevention and early detection by raising public awareness of the rising burden of CRC in young adults.

Breathing New Life Into Chemotherapy

March 02, 2020

Although the development of chemotherapy-free regimens is a major thrust of oncology research, improvements to traditional cytotoxic therapy are actively being explored, with a focus on new formulations and delivery methods for agents that have been used for decades.

Patients With Digestive Disorders Are More Likely to Develop GI Toxicities on Immunotherapy

February 28, 2020

Patients with preexisting inflammatory bowel disease have a significantly higher risk of developing gastrointestinal adverse events during treatment with an immunotherapybased anticancer regimen than those without inflammatory bowel disease.

Key Questions Surround CDK4/6 Inhibitors in HR+ Breast Cancer

February 28, 2020

During a recent OncLive Peer Exchange®, a panel of experts sought to answer several key questions regarding the management of advanced, hormone receptor–positive breast cancer, particularly with CDK4/6 inhibitors.